Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

License, Clinical Trial and Sponsored Research Agreements (Tables)

License, Clinical Trial and Sponsored Research Agreements (Tables)

6 Months Ended

Jun. 30, 2019

License, Clinical Trial and Sponsored Research Agreements

Schedule of Research and development for licenses

For the three months and six months ended June 30, 2019 and 2018, the Company recorded the following expense in research and development for licenses acquired:


	For the three months ended June 30,				For the six months ended June 30,
($ in thousands)	2019		2018		2019		2018
City of Hope
CD123	$	—	$	—	$	250	$	—
CS1		200		—		200		—
Manufacturing		—		—		—		75
Nationwide Children's Hospital - C134		—		—		200		—
Total	$	200	$	—	$	650	$	75

For the three months and six months ended June 30, 2019 and 2018, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:


	For the three months ended June 30,				For the six months ended June 30,
	2019		2018		2019		2018
($ in thousands)
City of Hope	$	500	$	500	$	1,000	$	1,000
City of Hope - CD123		456		114		759		264
City of Hope - IL13Rα2		225		143		567		503
City of Hope - Manufacturing		115		115		229		229
Fred Hutch - CD20		374		418		641		684
BIDMC - CRISPR		—		—		69		—
Total	$	1,670	$	1,290	$	3,265	$	2,680